Navigation Links
UK Must Maintain its Momentum in Stem Cell Expertise
Date:1/19/2009

LONDON, January 19 /PRNewswire/ -- Excalibur, the international investment house specialising in medical sciences, said today the UK must 'maintain its momentum' to deliver pioneering stem cell treatments if it is to remain at the forefront of medical technology.

Professor Sir Christopher Evans, founder and chairman of Excalibur, welcomed the announcement that ReNeuron plc has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a first-in-man clinical trial for the treatment of patients who have been left disabled by an ischaemic stroke.

Sir Christopher said: "We founded ReNeuron with Dr John Sinden and have invested in the company every step of the way for the last 10 years. We are proud the company has now reached this important milestone in its development of cell therapy treatment for stroke. There have been many scientific and financial hurdles to overcome during these years but we were determined to see this through.

"It is absolutely essential that we in the UK maintain our momentum in stem cell development and our belief in our ability to deliver these potentially revolutionary treatments. Too often in this country there is a tendency to focus on potentially negative outcomes but today's announcement is extremely important news for victims of stroke. At the end of the day lives - and the future of medicine in this area -- could be transformed by this science."

NOTES TO EDITORS

About Excalibur

Excalibur was launched in April 2008 following the acquisition of MVIL by Merlin Biosciences. Excalibur, which has a team of ten professionals, provides a wide range of investment and advisory services to the medical sciences sector. Its latest fund, Merlin Fund III, has successfully invested in a wide range of healthcare and medical sciences companies including PIramed which was sold for $185m in May 2008. Excalibur intends to replicate this successful investment strategy in the new funds that it is proposing to launch over the next 12 months.

Merlin originally founded ReNeuron in 1998 and has provided funding for the company over the last 10 years through Merlin 's Fund l and ll and has continued to invest in and support the company.

Further information: Ramsay Smith, Media House, +44(0)207-397-8459, Email:ramsay@mediahouse.co.uk, mobile +44(0)7788-414856.


'/>"/>
SOURCE Excalibur
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
2. Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained With Naproxen Sodium
3. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
4. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
5. Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
6. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
7. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
Breaking Medicine News(10 mins):